HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies.

作者: A H Arnaout , P M Dawson , S Soomro , P Taylor , N A Theodorou

DOI: 10.1136/JCP.45.8.726

关键词:

摘要: Paraffin wax sections of 70 surgically resected colorectal adenocarcinomas were examined for the overexpression HER2/c-erbB-2 oncoprotein using three different specific antibodies and avidin-biotin immunoperoxidase technique. The patients included 38 men 32 women aged between 47 80 years. tumours derived from various parts large intestinal tract, represented all stages Dukes' classification histological grades differentiation. Many tumour also adjacent normal or transitional mucosa. Eight tubular adenomas found in colectomy specimens association with some carcinomas examined. No positive membrane staining was seen any carcinomas, four adenomas, two hyperplastic polyps, nor It is suggested that c-erbB-2 gene product unlikely to be as common pronounced adenocarcinoma it ductal carcinoma breast.

参考文章(9)
S Paik, R Hazan, E R Fisher, R E Sass, B Fisher, C Redmond, J Schlessinger, M E Lippman, C R King, Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. Journal of Clinical Oncology. ,vol. 8, pp. 103- 112 ,(1990) , 10.1200/JCO.1990.8.1.103
Amanda McCann, Peter A. Dervan, P. A. Johnston, Desmond N. Carney, William J. Gullick, c-erbB-2 oncoprotein expression in primary human tumors Cancer. ,vol. 65, pp. 88- 92 ,(1990) , 10.1002/1097-0142(19900101)65:1<88::AID-CNCR2820650119>3.0.CO;2-Z
RA Walker, WJ Gullick, JM Varley, An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. British Journal of Cancer. ,vol. 60, pp. 426- 429 ,(1989) , 10.1038/BJC.1989.299
Jun Yokota, Kumao Toyoshima, Takashi Sugimura, Tadashi Yamamoto, Masaaki Terada, Hector Battifora, MartinJ Cline, Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. The Lancet. ,vol. 327, pp. 765- 767 ,(1986) , 10.1016/S0140-6736(86)91782-4
G Ong, W Gullick, K Sikora, Oncoprotein stability after tumour resection. British Journal of Cancer. ,vol. 61, pp. 538- 542 ,(1990) , 10.1038/BJC.1990.121
Pier G. Natali, Maria R. Nicotra, Aldo Bigotti, Irene Venturo, Dennis J. Slamon, Brian M. Fendly, Axel Ullrich, Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. International Journal of Cancer. ,vol. 45, pp. 457- 461 ,(1990) , 10.1002/IJC.2910450314
Robert M. Hudziak, Mary Anna Napier, Michael T. Lipari, Brian M. Fendly, Axel Ullrich, Marcy Winget, Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product Cancer Research. ,vol. 50, pp. 1550- 1558 ,(1990)
Y Shiloh, Z Josefberg, M Tal, D Givol, A Deutch, J Schlessinger, M Gutman, D Assaf, M Wetzler, R Kris, Sporadic Amplification of the HER2/neu Protooncogene in Adenocarcinomas of Various Tissues Cancer Research. ,vol. 48, pp. 1517- 1520 ,(1988)
D'Emilia J, Steele G, Wolf B, Summerhayes Ic, D'Ercole K, Bulovas K, Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon. Oncogene. ,vol. 4, pp. 1233- 1239 ,(1989)